Truckee, CA (UroToday.com) FDA has approved apalutamide, the first treatment for nonmetastatic castration-resistant prostate cancer, based on results from a phase 3 study that showed the drug reduced the risk of metastasis or death by 72% and improved median metastasis-free survival by more than 2 years. The study was recently presented at the 2018 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) in San Francisco and published in The New England Journal of Medicine. "In the trial supporting approval, Erleada had a robust effect on this endpoint".
The approval comes when Johnson & Johnson's blockbuster prostate cancer drug Zytiga is facing challenges.
"As the impact of prostate cancer continues to grow, we are reminded every day of the critical need for therapeutic options that offer patients with prostate cancer more time with their loved ones", added Dr Mark Scholz, executive director of the Prostate Cancer Research Institute.
Patients treated with apalutamide also had a significantly prolonged median time to symptomatic progression, progression-free survival, and time to metastasis, compared with placebo (P .001).
Typically cancer drugs are approved based on their ability to extend survival of patients or halt progression of disease, but the approval of Erleada was based on the drug preventing the cancer from spreading to other parts of the body. A previous study demonstrated that apalutamide prevented elevations of prostate-specific antigen (PSA), a prognostic factor for the development of metastases.
Megastar Amitabh Bachchan uploads resume on Twitter
The "Shahenshah" of Bollywood is known for his remarkable humour which goes hand in hand with his splendid on-screen presence. From his pictures of meeting fans on Sundays to remembering his old films, Big B often shares his opinions and comments.
The FDA has approved Johnson & Johnson's next generation prostate cancer drug, apalutamide in an early but tough to treat form of prostate cancer that has not spread.
The benefit was seen across patient subgroups, including in patients with high rates of disease progression. The primary endpoint was metastasis-free survival.
The green light comes months ahead of the FDA's target review date and is a big boost for J&J, which needs Erleada to hit the ground running and build momentum before Zytiga (abiraterone acetate) - its current blockbuster medicine for CRPC - faces generic competition in the United States, which accounted for around half of the drug's $2.5bn in sales in 2017. Participants were randomly assigned oral Erleada, or placebo, once daily.
The most common Grade 3/4 treatment-emergent adverse events (TEAEs) for ERLEADA in combination with ADT versus placebo in combination with ADT were rash (5.2 percent vs. 0.3 percent), fall (1.7 percent vs. 0.8 percent) and fracture (2.7 percent vs. 0.8 percent).
Related News:
-
Citigroup Raises Cisco Systems (CSCO) Price Target to $46.00
BHATT PRAT sold 25,638 shares worth $821,900. 121,390 shares were sold by Robbins Charles , worth $3.89M on Monday, September 11. The stock is now showing positive return of 4.69% throughout last week and witnessed rising return of 1.25% in one month period.Tripura Assembly polls: 23 pct turnout till 11 AM
In the 2016 by-elections, CPM wrested the Barjala seat from the Congress taking the Left tally to 51. The CPM is contesting 57 seats while the partners CPI, RSP and Forward Bloc are contesting one each.Strangers Are Surprised With Random Acts Of Kindness In Endicott
Residents and staff from Primrose Retirement Communities in Sioux Falls spent Thursday giving back to the community. The questions on kindness related to the National Random Acts of Kindness week which takes place February 11-17. -
SeaCrest Wealth Management LLC Invests $225000 in Pretium Resources Inc (PVG)
CIBC upgraded shares of Pretium Resources from a "neutral" rating to an "outperform" rating in a report on Thursday, October 12th. Golub Group Llc increased its stake in Bank Amer Corp (BAC) by 39.65% based on its latest 2017Q3 regulatory filing with the SEC.Chelsea star expected to return for Barcelona game
You have to try and compete with them at this level. "For sure, his performance was impressive", Conte said. In one side, you must be a bit sad to play against them, but on the other hand, you must be excited.Black NHL player Devante Smith-Pelly taunted by Chicago fans
And so was Caps head coach Barry Trotz, who condemned the fans' actions, and racism as a whole, after the game. Unfortunately, this isn't the first time that Smith-Pelly has been subjected to such treatment from fans. -
Marcelo, Sergio Ramos and Zidane's future — Real Madrid
The Wales winger was a second-half replacement for Benzema in Madrid's 3-1 Champions League defeat of Paris Saint-Germain midweek. "In a team like Real Madrid , arguments always arise when things are not going well", Kroos said, via Marca .Xbox gets mobile party chat on Android and iOS apps
Having this feature on mobile devices gives Microsoft a slight edge over Sony as the PlayStation app does not support voice chat. Stay connected to your gaming community on the go, control your Xbox One from the app, and buy new games from the store.Powerful 7.2 magnitude quake rocks Mexico City… again
Mexico's Interior Department said the officials were evaluating reports of damage from the natural disaster . But five women, four men, and the three children were killed, the Oaxaca prosecutor's office said. -
Killed in Shooting Outside Church in Russia's Dagestan Region
The Russian Investigative Committee says the gunman has been identified as a local resident in his early 20s. Dagestan is a predominantly Muslim region between Chechnya and the Caspian Sea close to Georgia.Kamal Haasan Meets Rajinikanth, No Word On Alliance
Rajinikanth and Kamal Haasan's relationship goes back decades, the duo has acted in several films together in the 1970s. He wished me good luck", Haasan said. "The opportunity might come to meet national leaders in the future".NVIDIA Corporation (NVDA) - EPS Growth Analysis
This is based on a 1-5 numeric scale where Rating Scale: 1.0 Strong Buy, 2.0 Buy, 3.0 Hold, 4.0 Sell, 5.0 Strong Sell. NVIDIA Corporation (NVDA ) stock price moved Upswing along with the volume 18.54 million shares in Wednesday session.